Ascendis Pharma A/S

Ascendis Pharma Misses on EPS, Stock Down 0.85%

Ascendis Pharma reported a larger-than-expected loss per share for the quarter, which contributed to a slight decline in its stock price. Investors may be concerned about the lack of revenue information and guidance, leading to uncertainty about the company's future performance. The stock's reaction reflects these concerns, with a decrease of 0.85% following the earnings report.